Paige Mahaney is Chief Scientific Officer of C4 Therapeutics, Inc.. Currently has a direct ownership of 105,000 shares of CCCC, which is worth approximately $316,050. The most recent transaction as insider was on Feb 14, 2025, when has been sold 28,200 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 105K
36.72% 3M change
n/a 12M change
Total Value Held $316,050

Paige Mahaney Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 14 2025
BUY
Grant, award, or other acquisition
-
28,200 Added 21.17%
105,000 Common Stock
Oct 28 2024
BUY
Grant, award, or other acquisition
-
76,800 Added 50.0%
76,800 Common Stock
PM

Paige Mahaney

Chief Scientific Officer
Watertown, MA

Track Institutional and Insider Activities on CCCC

Follow C4 Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CCCC shares.

Notify only if

Insider Trading

Get notified when an C4 Therapeutics, Inc. insider buys or sells CCCC shares.

Notify only if

News

Receive news related to C4 Therapeutics, Inc.

Track Activities on CCCC